CGRP Antibodies in Migraine

This program will include a discussion of off-label and investigational agents not approved by the FDA for use in the US and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

1970s to 1990s: Era of Characterizing Innervation and Neural Regulation of Cerebral Blood Vessels

Demonstration of Perivascular CGRP Nerves and Potent Vasodilation by CGRP in Cerebral Arteries

The Trigeminovascular Reflex

Triptans Suppress CGRP Release From Trigeminal Nerves Via Presynaptic 5-HT1B/D Receptors

CGRP-Targeting Therapy for Prevention and Acute Treatment of Migraine

Pharmacologic Characteristics of CGRP-Targeting mAbs

CGRP-Targeting mAbs for Migraine Prevention

CGRP-Targeting Small Molecules for the Treatment of Migraine

CGRP-Targeting mAbs: 50% Responder Rates in Phase 3 Studies of EM

CGRP-Targeting mAbs: 75% Responder Rates in Phase 3 Studies of EM

Considerations for Clinical Practice: Dosing and Onset of Action

Considerations for Clinical Practice: Adverse Events

Considerations for Clinical Practice: Patient and Treatment Factors

Conclusions

Abbreviations

Abbreviations (cont)